Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

And then thirdly, a number of patients who are already on CD20 label that progress as relapsing ... from our perspective and orthogonal to dupilumab. But also, subsequently we've worked out ...

Ebglyss, the third biologic targeting IL-13 for atopic dermatitis, follows Dupixent (dupilumab) and Adbry/Adtralza (tralokinumab ... for overcoming endocrine resistance in breast cancer. Label ...

EBGLYSS™, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT® (dupilumab ... endocrine resistance in breast cancer. Label expansions, including combination with IBRANCE ...

Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor ... $1 billion-plus by 2026 if approved with a broad label. Overall, the antibody cut the annual asthma ...

Now, experts are questioning if the FDA should reconsider these warning labels. Medscape Medical News, December 23, 2024 MMRV Safety Assessed in Children on Methotrexate, Dupilumab No adverse ...

Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab) was approved to treat ... test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

These medications include Dupixent (dupilumab), approved by the Food and ... inhalers may be risky if you do not read the medication labels carefully. Since there is no real inhaler color meaning ...